tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

HILS

Hillstream BioPharma to change corporate name to Tharimmune
The FlyHillstream BioPharma to change corporate name to Tharimmune
7M ago
HILS
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
PremiumPress Releases
Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
7M ago
HILS
Hillstream agrees to acquire clinical stage asset for chronic pruritis
PremiumThe Fly
Hillstream agrees to acquire clinical stage asset for chronic pruritis
7M ago
HILS
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
PremiumPress Releases
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
7M ago
HILS
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
PremiumPress Releases
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
8M ago
HILS
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
PremiumPress ReleasesHillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
9M ago
HILS
Hillstream BioPharma expands collaboration with Minotaur, OmniAb
PremiumThe Fly
Hillstream BioPharma expands collaboration with Minotaur, OmniAb
9M ago
HILS
OABI
Hillstream BioPharma downgraded to Neutral from Buy at Dawson James
PremiumThe Fly
Hillstream BioPharma downgraded to Neutral from Buy at Dawson James
9M ago
HILS
Hillstream BioPharma appoints Sireesh Appajosyula as COO
PremiumThe Fly
Hillstream BioPharma appoints Sireesh Appajosyula as COO
9M ago
HILS
Hillstream BioPharma announces strategic reprioritization of pipeline
PremiumThe Fly
Hillstream BioPharma announces strategic reprioritization of pipeline
9M ago
HILS
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
PremiumPress Releases
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
9M ago
HILS
Hillstream BioPharma licenses technology for proprietary antibody conjugates
PremiumThe Fly
Hillstream BioPharma licenses technology for proprietary antibody conjugates
10M ago
HILS
Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers
PremiumPress ReleasesHillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers
10M ago
HILS
Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
PremiumPress Releases
Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
11M ago
HILS
Hillstream BioPharma Announces Closing of Public Offering of Common Stock
PremiumPress Releases
Hillstream BioPharma Announces Closing of Public Offering of Common Stock
12M ago
HILS
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
PremiumPress Releases
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
12M ago
HILS
Hillstream BioPharma prices 5.3M share public offering at 50c per share
PremiumThe Fly
Hillstream BioPharma prices 5.3M share public offering at 50c per share
12M ago
HILS
Hillstream BioPharma Announces Pricing of Public Offering
PremiumPress Releases
Hillstream BioPharma Announces Pricing of Public Offering
12M ago
HILS
Hillstream BioPharma Announces Proposed Public Offering
PremiumPress Releases
Hillstream BioPharma Announces Proposed Public Offering
12M ago
HILS
Hillstream BioPharma announces common stock offering, no amount given
PremiumThe FlyHillstream BioPharma announces common stock offering, no amount given
12M ago
HILS
Hillstream BioPharma selects OncoBay to advance development of HSB-1216
PremiumThe Fly
Hillstream BioPharma selects OncoBay to advance development of HSB-1216
1y ago
HILS
Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism
PremiumPress Releases
Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism
1y ago
HILS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >